ARTICLE | Clinical News
BDM-E: Phase I/II data
July 24, 2006 7:00 AM UTC
Data from 15 evaluable patients in a double-blind, placebo-controlled Phase I/II study showed that subcutaneous BDM-E did not cause any adverse effects. BDM-E was administered for 10 days with follow-...